Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
folfiri + bevacizumab + iparomlimab
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
folfiri + bevacizumab + QL1706 is an investigational combination therapy being evaluated for the treatment of metastatic colorectal cancer (mCRC). The regimen combines the standard-of-care FOLFIRI chemotherapy (comprising folinic acid, fluorouracil, and irinotecan) and the anti-angiogenic agent bevacizumab with QL1706 (also known as iparomlimab). QL1706 is a novel bifunctional immunotherapy developed by Qilu Pharmaceutical using "Mab-Pair" technology, which simultaneously targets the PD-1 and CTLA-4 immune checkpoints. This combination strategy is designed to enhance anti-tumor activity in patients with microsatellite stable (MSS) tumors, which are typically resistant to single-agent checkpoint inhibitors, by leveraging the synergistic effects of cytotoxic chemotherapy, VEGF inhibition, and dual checkpoint blockade. It is currently in Phase II/III clinical development as a second-line therapy for patients who have progressed on prior treatments.
- Other names
- FOLFIRI + bevacizumab + QL1706FOLFIRI + bevacizumab + iparomlimab and tuvonralimabaipalolitovorelizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFA (Vascular endothelial growth factor A)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on folfiri + bevacizumab + iparomlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on folfiri + bevacizumab + iparomlimab.